Red Blood Cells: A New Frontier for Biologic Drug Delivery
A recent study in Molecular Pharmaceutics investigates a novel strategy to improve the pharmacokinetics of biologic drugs by targeting them to red blood cells (RBCs). The research evaluates whether attaching biologics to RBCs can extend their half-life in circulation and reduce nonspecific uptake into tissues, a common challenge that limits efficacy and increases side effects. This approach represents a significant innovation in drug delivery, moving beyond traditional formulations to leverage the body’s own cellular components for more precise therapeutic monitoring and delivery.
Study Significance: For professionals in laboratory medicine and clinical chemistry, this research underscores the evolving interface between therapeutic drug monitoring (TDM) and advanced drug delivery systems. The potential to modulate a drug’s half-life and distribution via RBC targeting could directly impact how assays are developed and validated for these next-generation biologics. It suggests future diagnostic algorithms may need to account for drug-carrier complexes, influencing pre-analytical handling, reference ranges, and the interpretation of pharmacokinetic data in patient care.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
